Health Care · Biological Products, (No Diagnostic Substances)

TECH Bio-Techne SEC Filings & Insider Trading Activity 2026

company
CIK 842023149 filings
S&P 500

TECH at a glance

Bio-Techne (TECH, SEC CIK 842023) filed its latest 10-K annual report on August 24, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended June 30, 2026 (FY2026), Bio-Techne (TECH) reported revenue of $1.2 billion (down 0.4% from FY2025) and net income of $181.8 million. Diluted EPS was $1.16.
  • As of September 30, 2026, 35 institutional investment managers tracked by SignalX reported holding Bio-Techne (TECH) shares worth $4.6 billion in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2026
$1.2B
−0.4% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
35 funds
$4.6B · −2 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Jun 30, 2026

Full analysis →

Business Overview

  • Core business model: Develop, manufacture, and sell life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets globally
  • New emphasis on Diagnostics and Spatial Biology segment with Lunaphore acquisition in fiscal 2024 enhancing automated spatial biology solutions
  • Strategic move toward integration as Merck KGaA merger announced in June 2026 with $73.00/share cash offer, expected closing late 2026/early 2027
  • Employee base steady at ~3,000 globally with 48% female and 22% nonwhite representation; 1,900+ new products introduced in fiscal 2026
  • Diagnostics and Spatial Biology segment now ~28% of net revenues, reflecting increased focus and expansion into adjacent diagnostics markets

Risk Factors

  • Regulatory risk: U.S. FDA regulation changes on drug pricing and lab developed tests impacting Diagnostics segment demand and profitability
  • Macroeconomic threat: 48% sales outside U.S. exposed to tariffs, geopolitical tensions including U.S.-China trade, raising supply/import costs
  • Operational risk: Sole or limited source suppliers and complex FDA-regulated manufacturing may cause production delays and capacity constraints
  • Competitive risk: Lunaphore spatial biology solutions acquisition targets rapid innovation, but competitive pressure from multinational and start-ups persists
  • Financial risk: $200M drawn on $1B revolving credit facility with covenants limiting transactions, increasing vulnerability to economic or interest rate changes

Management Discussion & Analysis

  • Revenue $1.215B, flat YoY (FY26 vs. FY25); Protein Sciences up 1% to $874.6M, Diagnostics down 3% to $336.4M
  • Operating gross margin 65.8% vs 64.8%, adjusted gross margin 69.6% vs 70.4%; Protein Sciences margin 75.0% vs 75.6%, Diagnostics margin 55.2% vs 57.3%
  • Best segment Protein Sciences: sales $874.6M, +1% YoY; worst Diagnostics: sales $336.4M, -3% YoY, impacted by held-for-sale business divestiture
  • Cash flow from operations $292.1M; dividends paid $49.9M; share repurchases $41.7M; capex $28.9M; cash & investments $264.7M, up from $162.2M
  • Merger agreement signed with Merck KGaA for $73/share cash buyout; merger expected late 2026 or early 2027; execution subject to regulatory and shareholder approvals

AI summary of the TECH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $299.7M, up 5% YoY from $286.6M
  • Gross margin 65.6% vs 65.6% YoY, adjusted margin 69.3% vs 70.2%
  • Protein Sciences best performer: sales $219.7M, up 9%; operating margin 37.9% vs 38.4%
  • Diagnostics and Spatial Biology weakest: sales $80.2M, up 1%; operating margin 7.4% vs 11.2%
  • Cash $350.0M vs $264.7M; operating cash flow $73.1M vs $27.6M, capital expenditures $5.9M and $12.6M dividends

Risk Factors

  • No material changes to previously disclosed risk factors during the quarter ended September 30, 2026
  • Carried-forward risks include macroeconomic conditions affecting demand and operating results
  • Carried-forward risks include competition and technological change in life-science markets
  • Carried-forward risks include liquidity, debt, and foreign-currency exposure

AI summary of the TECH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 8.01: Other Events

  • Bio-Techne announced a cash dividend in its November 3, 2026 press release
  • Dividend announcement signals a direct shareholder return and may affect income-oriented investor expectations

Item EX-99.1: Item EX-99.1

  • Quarterly dividend: $0.08 per share for the quarter ended September 30, 2026
  • Payment November 23, 2026 to shareholders of record November 13, 2026
Filed Sep 23, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Merger approved by shareholders, clearing a key condition for Merck KGaA’s acquisition of Bio-Techne
  • 121.93M votes for versus 1.21M against, with 30,610 abstentions

Item EX-99.1: Item EX-99.1

  • Shareholders approved Merck KGaA’s proposed acquisition, removing a key transaction condition
  • Hart-Scott-Rodino waiting period expired September 18, 2026, reducing U.S. antitrust execution risk

Item 7.01: Regulation FD Disclosure

  • Shareholders approved the Merger Agreement Proposal on September 23, 2026
  • Approval clears the shareholder voting condition for Bio-Techne’s proposed merger
Filed Sep 14, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • References February 11, 2026 Form 8-K for officer appointments and compensation arrangements
  • Executive and director ownership changes reported through SEC Forms 3 or 4

Item 8.01: Other Events

  • Merger litigation emerged: shareholder lawsuit seeks to enjoin the September 23, 2026 vote, creating execution and timing risk
  • Multiple demand letters challenge proxy disclosures, though Bio-Techne disputes the allegations and estimates no potential loss

AI summaries of TECH 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TECH

Don't miss the next TECH filing

  • Alerts as it files. A push when TECH files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TECH, by share count.
  • Ask anything. An AI agent that reads every TECH filing and answers with sources.

TECH alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Hippel JamesFNov 1, 2026$72.66
Hippel JamesMNov 1, 2026-
Hippel JamesMNov 1, 2026-
Kelderman KimFNov 1, 2026$72.66
Vessey RupertAOct 29, 2026-
BAUMGARTNER ROBERT VAOct 29, 2026-
Herr Amy E.AOct 29, 2026-
Bushman Julie LAOct 29, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2024FY2025FY2026
Profitability
Revenue-$1.2B$1.2B
Gross Profit-$790.3M$799.1M
Operating Income-$102.3M$251.9M
Net Income-$73.4M$181.8M
Gross Margin-64.8%65.8%
Op. Margin-8.4%20.7%
Net Margin-6.0%15.0%
Balance Sheet
Total Assets$2.7B$2.6B$2.6B
Equity-$1.9B$2.1B
ROE-3.8%8.6%
Per Share
EPS-$0.46$1.16
Cash Flow
Operating CF-$287.6M$292.1M
CapEx$62.9M$31.0M$28.9M

Source: XBRL data in Bio-Techne (TECH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TECH share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TECH shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202635$4.59B
Q2 202637$5.75B
Q1 202635$3.76B
Q4 202530$3.97B
Q3 202532$3.61B
Q2 202531$3.86B
Q1 202527$2.94B
Q4 202424$3.15B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 251 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TECH filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 6, 2026Analysis
8-KNov 4, 2026Analysis-
4Nov 3, 2026--
4Nov 3, 2026--
4Nov 2, 2026--
4Nov 2, 2026--
4Nov 2, 2026--
4Nov 2, 2026--
4Nov 2, 2026--
4Nov 2, 2026--
4Nov 2, 2026--
4Nov 2, 2026--
4Nov 2, 2026--
4Nov 2, 2026--
4Nov 2, 2026--
4Nov 2, 2026--
4Sep 30, 2026--
4Sep 24, 2026--
8-KSep 23, 2026Analysis-
8-KSep 14, 2026Analysis-
10-KAug 24, 2026Analysis
4Aug 19, 2026--
4Aug 19, 2026--
4Aug 19, 2026--
4Aug 19, 2026--

Related Health Care companies

All Health Care →

TECH SEC filings: frequently asked questions

Which institutions hold TECH stock?

As of September 30, 2026, the largest Bio-Techne (TECH) holders among the 13F filers tracked by SignalX were BlackRock ($1.0 billion), Vanguard Capital Management LLC ($742.9 million), Vanguard Portfolio Management LLC ($460.1 million), State Street Corp ($438.1 million), Goldman Sachs Group ($300.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was TECH's revenue in fiscal year 2026?

For the fiscal year ended June 30, 2026 (FY2026), Bio-Techne (TECH) reported revenue of $1.2 billion (down 0.4% from FY2025) and net income of $181.8 million. Diluted EPS was $1.16. The figures come from the XBRL data in the 10-K.

What are the main risks in TECH's latest 10-K?

In the 10-K filed August 24, 2026, Bio-Techne (TECH) flagged: Regulatory risk: U.S. FDA regulation changes on drug pricing and lab developed tests impacting Diagnostics segment demand and profitability. Macroeconomic threat: 48% sales outside U.S. exposed to tariffs, geopolitical tensions including U.S.-China trade, raising supply/import costs. (AI summary of the Risk Factors section.)

What did TECH report in its latest 8-K?

Bio-Techne (TECH) filed an 8-K on November 4, 2026 reporting Item 8.01 (Other Events). Bio-Techne announced a cash dividend in its November 3, 2026 press release.

What are the latest TECH SEC filings?

Bio-Techne (TECH) filed its latest 10-K annual report on August 24, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 3, 2026.

What is TECH's SEC CIK number?

Bio-Techne (TECH)'s SEC Central Index Key (CIK) is 842023. EDGAR lists every TECH filing under that number.

Ask anything about TECH

The research agent reads TECH's filings, financials, insider trades and 13F holders, then answers with sources.